United States Drug Patent 8,772,353: Scope, Claims, and Landscape Analysis

This report details United States Patent 8,772,353, examining its claims, scope, and the broader patent landscape relevant to its asserted technologies. The patent, granted on September 16, 2014, to Bristol-Myers Squibb Company, describes and claims novel compounds and their use in treating various medical conditions.

What is the Core Technology of Patent 8,772,353?

Patent 8,772,353 primarily covers specific chemical compounds and their pharmaceutical applications. The patent's abstract indicates a focus on selective inhibitors of the Bruton's tyrosine kinase (BTK) enzyme. BTK is a critical component of the B-cell receptor (BCR) signaling pathway, which is implicated in the development and progression of various B-cell malignancies and autoimmune diseases. Inhibiting BTK can disrupt these signaling pathways, offering therapeutic benefits.

The patent's claims define a genus of chemical compounds with a specific structural formula, including defined substituent groups. It also claims specific compounds within this genus, pharmaceutical compositions containing these compounds, and methods of treating diseases using these compounds.

What Specific Inventions are Claimed?

Patent 8,772,353 contains multiple claims, each delineating a distinct aspect of the invention. The claims can be broadly categorized as follows:

Compound Claims: These claims define the chemical structure of the claimed inventions.
- Claim 1 is an independent claim defining a genus of compounds with a general structural formula. This formula includes several variable positions (R1, R2, R3, R4, R5, R6, R7) and lists the possible chemical groups that can occupy these positions. The claim specifies a particular fused bicyclic core structure.
- Claims 2-18 are dependent claims that narrow the scope of Claim 1 by providing specific examples of substituents or further defining the core structure. For instance, they may specify particular heterocyclic rings, alkyl groups, or aryl groups at various positions.
- Claims 19-21 claim specific, named compounds that fall within the structural definition of Claim 1. These are often referred to as "exemplified compounds" within the patent.
Composition Claims: These claims cover pharmaceutical formulations incorporating the claimed compounds.
- Claim 22 is an independent claim for a pharmaceutical composition comprising one of the claimed compounds and a pharmaceutically acceptable carrier. This claim is broad and encompasses various dosage forms and delivery methods.
- Claim 23 is a dependent claim that further specifies the composition, potentially by indicating a particular type of carrier or excipient.
Method of Treatment Claims: These claims cover the use of the claimed compounds for therapeutic purposes.
- Claim 24 is an independent claim for a method of treating a disease, disorder, or condition, comprising administering to a subject a therapeutically effective amount of one of the claimed compounds. The claim lists several target diseases, including B-cell malignancies such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL), as well as autoimmune diseases.
- Claim 25 is a dependent claim that specifies particular types of B-cell malignancies or autoimmune conditions to be treated.
- Claim 26 is a dependent claim that specifies the dosage or frequency of administration of the compound.

The patent also includes Markush claims, which are common in chemical patents. These claims define a group of related chemical structures by specifying a common core structure with variable substituents. This allows for protection of a broad range of structurally similar compounds that are expected to have similar properties.

What is the Claimed Scope of the Patent?

The scope of Patent 8,772,353 is defined by the language of its claims, particularly the independent claims.

Chemical Scope: Claim 1 establishes a broad chemical genus of BTK inhibitors. The precise substituents listed for R1 through R7, along with the specific fused bicyclic core, define the boundaries of this genus. Any compound that falls within this structural definition, even if not explicitly named, is considered to be within the scope of the claim. The dependent claims and exemplified compounds further illustrate specific embodiments that are definitively covered.
Therapeutic Scope: Claim 24 provides a broad therapeutic scope, covering methods of treating a range of B-cell malignancies and autoimmune diseases. The listing of specific diseases like CLL, SLL, and MCL indicates the intended therapeutic targets. The phrase "therapeutically effective amount" is standard and refers to the quantity of the compound that produces the desired therapeutic effect without causing undue toxicity.
Formulation Scope: Claim 22 covers any pharmaceutical composition containing a claimed compound and a pharmaceutically acceptable carrier. This broadens the protection beyond the active pharmaceutical ingredient (API) itself to include the final drug product.

The patent's scope is therefore extensive, covering the chemical entities, their pharmaceutical formulations, and their therapeutic applications in specific disease areas.

What is the Role of BTK Inhibition in Disease?

Bruton's tyrosine kinase (BTK) plays a crucial role in the development and function of B-cells. It is a key signaling molecule in the B-cell receptor (BCR) pathway, which is essential for B-cell proliferation, differentiation, and survival [1]. In certain hematological malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), the BCR pathway is constitutively activated, leading to uncontrolled B-cell growth [2].

By inhibiting BTK, drugs like those claimed in patent 8,772,353 can disrupt this aberrant signaling, leading to:

Reduced B-cell proliferation: Blocking BTK signaling limits the signals that promote B-cell division.
Induction of apoptosis: Inhibition can trigger programmed cell death in malignant B-cells.
Decreased B-cell adhesion and migration: BTK is involved in the interaction of B-cells with the bone marrow microenvironment, which supports their survival. Inhibiting BTK can disrupt this interaction [3].

In autoimmune diseases, dysregulated B-cell activity also contributes to pathology. BTK inhibition can reduce the production of autoantibodies and dampen inflammatory responses mediated by B-cells, offering a therapeutic avenue for conditions like rheumatoid arthritis and lupus [4].

What is the Patent Landscape for BTK Inhibitors?

The patent landscape for BTK inhibitors is highly competitive and dynamic. Several companies have developed and patented BTK-targeting therapies. Key players and their notable patented compounds and approved drugs include:

Company	Key Compound/Drug	Patent Identifier (Example)	Therapeutic Area (Approved)
AbbVie/Pharmacyclics	Ibrutinib (Imbruvica)	US 8,653,077	CLL, MCL, Waldenstrom's Macroglobulinemia, CLL/SLL, MCL
Eli Lilly and Company	Acalabrutinib (Calquence)	US 8,846,942	MCL, CLL/SLL
BeiGene	Zanubrutinib (Brukinsa)	US 9,783,551	MCL, CLL/SLL, WM, MZL
AstraZeneca	Calquence (Acalabrutinib)	US 8,846,942	MCL, CLL/SLL

Note: Patent identifiers listed are examples and may not represent the entirety of a company's patent portfolio for these drugs.

Patent 8,772,353 from Bristol-Myers Squibb is part of this broader landscape. It claims a specific class of BTK inhibitors, distinct from the chemical structures of approved drugs like ibrutinib. However, the broad claims related to the treatment of B-cell malignancies and autoimmune diseases mean that this patent could potentially intersect with or create licensing opportunities with other BTK inhibitor developers.

The competitive nature of this field means that patent protection is a critical factor. Companies invest heavily in securing broad patent claims that cover not only the active compound but also its therapeutic uses and formulations. The expiration of key patents can lead to the entry of generic competitors, significantly impacting market dynamics.

What is the Prosecution History of Patent 8,772,353?

Understanding the prosecution history of a patent can reveal insights into the scope of protection and the prior art considered by the patent office. The examination process for Patent 8,772,353 involved interactions with the United States Patent and Trademark Office (USPTO).

During prosecution, patent examiners review the claims against existing prior art (e.g., previously published patents, scientific literature). Amendments to the claims are often made to distinguish the claimed invention from prior art and to clarify the scope of protection. The arguments presented by the applicant and the examiner's rejections and allowances provide a record of how the claims were narrowed or confirmed.

Specific details of the prosecution history, including office actions, applicant responses, and claim amendments, are publicly available through the USPTO's database (e.g., Public PAIR system). Analyzing this history would reveal:

Prior Art Cited: The specific patents and publications the USPTO examiner identified as relevant.
Claim Amendments: How the original claims were modified to overcome prior art rejections. For example, the applicant might have narrowed the substituent definitions or added specific limitations to the method of treatment claims.
Examiner's Objections: Any objections raised regarding clarity, enablement, or novelty.
Arguments Presented: The applicant's legal and technical arguments for patentability.

This detailed analysis of the prosecution history is crucial for a comprehensive understanding of the patent's enforceability and its precise scope in light of the prior art. For instance, if the examiner rejected claims based on a known BTK inhibitor with a very similar core structure, the applicant may have amended the claims to include specific structural features that were not present in the prior art.

What are Potential Infringement Considerations?

Potential infringement of Patent 8,772,353 would arise if a third party makes, uses, sells, offers for sale, or imports into the United States a product or process that falls within the scope of one or more of its claims, without authorization from Bristol-Myers Squibb.

Key considerations for infringement analysis include:

Compound Infringement: A competitor developing and marketing a compound that has a chemical structure identical or substantially similar to one of the compounds claimed in Patent 8,772,353. This involves a careful comparison of the competitor's compound's structure against the structural formula and specific exemplified compounds in the patent claims.
Composition Infringement: A competitor marketing a pharmaceutical formulation containing a claimed compound and a pharmaceutically acceptable carrier.
Method of Treatment Infringement: A competitor promoting or facilitating the use of a claimed compound for treating any of the diseases listed in Claim 24, especially if they provide instructions or support for such use. This can be complex, as direct infringement requires the act of treatment using the patented method. However, indirect infringement (e.g., inducing infringement or contributory infringement) can also be a concern.

Claim Construction: The interpretation of patent claims, known as claim construction or Markman proceedings, is critical. Courts will interpret the specific terms used in the claims to define their boundaries. This interpretation can significantly affect the breadth of the claims and, consequently, the likelihood of infringement. For example, the definition of specific substituents (R1-R7) in Claim 1 would be subject to rigorous interpretation.

Prior Art and Validity Challenges: Competitors may challenge the validity of Patent 8,772,353 by presenting new prior art or arguing that the patent does not meet the statutory requirements for patentability (e.g., novelty, non-obviousness, enablement). If a patent is found invalid, it cannot be infringed.

Freedom-to-Operate (FTO) Analysis: Companies seeking to develop BTK inhibitors would conduct FTO analyses to ensure their proposed products and activities do not infringe existing patents, including Patent 8,772,353. This involves mapping the competitor's product against the claims of relevant patents.

Given that Bristol-Myers Squibb is a major pharmaceutical company, it is likely to actively monitor the market for potential infringements of its patents and to take legal action where necessary to protect its intellectual property.

What is the Potential Commercial Impact?

The commercial impact of Patent 8,772,353 is tied to the success of the compounds it claims. If Bristol-Myers Squibb develops and successfully commercializes a drug based on the claimed BTK inhibitors, this patent would provide market exclusivity for a significant period (typically 20 years from the filing date, subject to patent term extensions).

The market for BTK inhibitors is substantial, driven by the prevalence of B-cell malignancies and the growing recognition of BTK's role in autoimmune diseases. Drugs like ibrutinib have achieved blockbuster status, generating billions of dollars in annual revenue. If the compounds claimed in Patent 8,772,353 prove to be effective and safe, they could capture a significant share of this market.

However, the commercial success also depends on several factors beyond patent protection:

Clinical Efficacy and Safety: The compounds must demonstrate superior efficacy or a better safety profile compared to existing treatments.
Regulatory Approval: Successful navigation of the FDA approval process is essential.
Market Competition: The competitive landscape, including other BTK inhibitors and alternative therapeutic modalities, will influence market penetration and pricing.
Patent Expiration and Generic Entry: Once the patent expires, generic competition can dramatically reduce drug prices and market share for the originator.
Manufacturing and Supply Chain: The ability to efficiently and cost-effectively manufacture the drug at scale.

The broad claims covering multiple diseases mean that a single successful compound could address a significant unmet medical need across various indications, amplifying its commercial potential.

Key Takeaways

United States Patent 8,772,353, granted to Bristol-Myers Squibb Company, claims a genus of selective Bruton's tyrosine kinase (BTK) inhibitors, their pharmaceutical compositions, and methods for treating B-cell malignancies and autoimmune diseases.
The patent's claims define a specific chemical structure with variable substituents and broadly cover therapeutic applications for conditions like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
The BTK pathway is a critical target in B-cell signaling, making inhibitors valuable in oncology and immunology.
The BTK inhibitor patent landscape is crowded, with major pharmaceutical companies holding significant portfolios of related intellectual property.
Infringement considerations focus on third-party activities that fall within the defined scope of the patent's compound, composition, or method of treatment claims.
The commercial impact hinges on the clinical success, regulatory approval, and market competitiveness of drugs developed under this patent.

Frequently Asked Questions

What are the specific chemical limitations that define the compounds claimed in Patent 8,772,353? Claim 1 of the patent outlines a general structural formula with specific definitions for several variable positions (R1 through R7) and a particular fused bicyclic core. These definitions precisely delineate the boundaries of the claimed chemical genus.
Does Patent 8,772,353 claim the drug Ibrutinib (Imbruvica)? No, Patent 8,772,353 claims a distinct set of chemical structures. Ibrutinib's chemical structure is covered by other patents, such as US 8,653,077.
What diseases are specifically mentioned in the method of treatment claims of Patent 8,772,353? The method of treatment claims, particularly Claim 24, specify B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL), as well as autoimmune diseases.
What is the significance of the "therapeutically effective amount" language in the method of treatment claims? This phrase indicates that the claimed method requires the administration of a dosage of the compound that is sufficient to produce a discernible and beneficial therapeutic effect in the treated subject for the specified condition.
Can a company develop a BTK inhibitor and avoid infringing Patent 8,772,353? A company can avoid infringement by ensuring their compound's chemical structure does not fall within the scope of the patent's claims, by not marketing compositions that infringe, and by not practicing the claimed methods of treatment. A thorough freedom-to-operate analysis is essential to assess this risk.

Citations

[1] Burger, J. A., & Teirstein, A. (2014). Bruton's tyrosine kinase inhibitors. Clinical Lymphoma, Myeloma and Leukemia, 14(3), 193-203.

[2] Pan, J., Wu, J., Xu, G., & Chen, J. (2017). Targeted therapies in B-cell lymphomas. Cancer Letters, 400, 43-51.

[3] Patschan, O., & Burger, J. A. (2015). B-cell receptor signaling in B-cell lymphomas. Current Opinion in Hematology, 22(6), 564-571.

[4] Clark, R. A., & Calabrese, L. H. (2017). Bruton's tyrosine kinase inhibitors for autoimmune diseases. Expert Opinion on Investigational Drugs, 26(6), 647-650.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1713458	⤷ Start Trial	CA 2015 00031	Denmark	⤷ Start Trial
European Patent Office	1713458	⤷ Start Trial	C300742	Netherlands	⤷ Start Trial
European Patent Office	1713458	⤷ Start Trial	92736	Luxembourg	⤷ Start Trial
European Patent Office	1713458	⤷ Start Trial	PA2015023	Lithuania	⤷ Start Trial
European Patent Office	1713458	⤷ Start Trial	15C0041	France	⤷ Start Trial
European Patent Office	1713458	⤷ Start Trial	CR 2015 00031	Denmark	⤷ Start Trial
European Patent Office	1713458	⤷ Start Trial	C20150029 00165	Estonia	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,772,353

Summary for Patent: 8,772,353